Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion. Methods: A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included. Results: The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4.1 months. Various modalities of treatment were initially employed including surgical resection (10.9%), repeated transarterial chemoembolization (TACE) (42.5%), and conservative management (42.9%). Among the patients with obstructive jaundice (n=88), successful biliary drainage was associated with better overall survival rate. Among the patients with BCLC stage C, overall survival differed depending on the initial treatment for HCC; surgical resection, TACE, systemic chemotherapy, and conservative management showed overall survival rates of 11.5, 6.0 ,2.4, and 1.6 months, respectively. After adjusting for confounders, surgical resection and repeated TACE were significant prognostic factors for HCC patients with bile duct invasion (hazard ratios 0.47 and 0.39, Ps <0.001, respectively). Conclusions: The survival of HCC patients with bile duct invasion at initial diagnosis is generally poor. However, aggressive treatments for HCC such as resection or biliary drainage may be beneficial therapeutic options for patients with preserved liver function
Abstract
Background/Aims: Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion. Methods: A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included. Results: The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4.1 months. Various modalities of treatment were initially employed including surgical resection (10.9%), repeated transarterial chemoembolization (TACE) (42.5%), and conservative management (42.9%). Among the patients with obstructive jaundice (n=88), successful biliary drainage was associated with better overall survival rate. Among the patients with BCLC stage C, overall survival differed depending on the initial treatment for HCC; surgical resection, TACE, systemic chemotherapy, and conservative management showed overall survival rates of 11.5, 6.0 ,2.4, and 1.6 months, respectively. After adjusting for confounders, surgical resection and repeated TACE were significant prognostic factors for HCC patients with bile duct invasion (hazard ratios 0.47 and 0.39, Ps <0.001, respectively). Conclusions: The survival of HCC patients with bile duct invasion at initial diagnosis is generally poor. However, aggressive treatments for HCC such as resection or biliary drainage may be beneficial therapeutic options for patients with preserved liver function
참고문헌 (34)
- Ferlay J, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
- Minagawa M, "Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC", UICC TNM systems in a cohort of 13,772 patients in Japan, 2007, pp.245, 909~922
- Llovet JM, "Prognosis of hepatocellular carcinoma: the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
- Kojiro M, "Hepatocellular carcinoma presenting as intrabile duct tumor growth:a clinicopathologic study of 24 cases", Cancer, 49, pp.2144~2147 (1982)
- Chen MF, "Obstructive jaundice secondary to ruptured hepatocellular carcinoma into the common bile duct. Surgical experiences of 20 cases", Cancer, 73, pp.1335~1340 (1994)
- Peng BG, "Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi", World J Gastroenterol, 11, pp.3966~3969 (2005)
- Lau WY, "Management of hepatocellular carcinoma presenting as obstructive jaundice", Am J Surg, 160, pp.280~282 (1990)
- Huang JF, "Incidence and clinical outcome of icteric type hepatocellular carcinoma", J Gastroenterol Hepatol, 17, pp.190~195 (2002)
- 서양권, "Effective Biliary Drainage and Proper Treatment Improve Outcomes of Hepatocellular Carcinoma with Obstructive Jaundice", Gut and Liver, 8(5), pp.526~535 (2014), 거트앤리버 발행위원회
- Huang GT, "Chen DS. Icteric type hepatocellular carcinoma: revisited 20 years later", J Gastroenterol, 33, pp.53~56 (1998)
- Choi J, "Clinical usefulness of endoscopic palliation in patients with biliary obstruction caused by hepatocellular carcinoma", Digestion, 88, pp.87~94 (2013)
- Kasai Y, "Hepatocellular carcinoma with bile duct tumor thrombus: surgical outcomes and the prognostic impact of concomitant major vascular invasion", World J Surg, 39, pp.1485~1493 (2015)
- Meng KW, "Clinical characteristics and surgical prognosis of hepatocellular carcinoma with bile duct invasion", Gastroenterol Res Pract, 2014, pp.604971~ (2014)
- Moon DB, "Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus:a Korean multicenter study", World J Surg, 37, pp.443~451 (2013)
- Yu XH, "Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi", Dig Dis Sci, 56, pp.252~259 (2011)
- Edge SB, "The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Chopra S, "Helical CT cholangiography with oral cholecystographic contrast material", Radiology, 214, pp.596~601 (2000)
- Holm AN, "What should be done with a dilated bile duct?", Curr Gastroenterol Rep, 12, pp.150~156 (2010)
- European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Paik WH, "Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach", Gastrointest Endosc, 69, pp.55~62 (2009)
- Yoon WJ, "A comparison of covered and uncovered wallstents for the management of distal malignant biliary obstruction", Gastrointest Endosc, 63, pp.996~1000 (2006)
- De Palma GD, "Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study", Gastrointest Endosc, 53, pp.547~553 (2001)
- Hong HP, "Percutaneous metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma", J Vasc Interv Radiol, 19, pp.748~754 (2008)
- Kim KM, "Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion", J Gastroenterol Hepatol, 24, pp.806~814 (2009)
- Lau WY, "Obstructive jaundice secondary to hepatocellular carcinoma", Surg Oncol, 4, pp.303~308 (1995)
- Satoh S, "Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi", Surgery, 128, pp.779~783 (2000)
- Shiomi M, "Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management", Surgery, 129, pp.692~698 (2001)
- Kwak HW, "Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area", J Gastroenterol Hepatol, 29, pp.820~829 (2014)
- Kanwal F, "Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network", Aliment Pharmacol Ther, 36, pp.257~265 (2012)
- Shao W, "Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi", World J Surg Oncol, 9, pp.2~ (2011)
- Ikenaga N, "Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion", J Gastrointest Surg, 13, pp.492~497 (2009)
- Hu J, "Obstructive jaundice caused by tumor emboli from hepatocellular carcinoma", Am Surg, 65, pp.406~410 (1999)
- Raoul JL, "Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization", Cancer Treat Rev, 37, pp.212~220 (2011)